Home
Clinical Trials
TO ASSESS THE EFFICACY AND SA...

TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE

Last Updated: 2023-04-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

460 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-29

Study Completion Date

2022-02-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

NCT02996500

Rheumatoid Arthritis

COMPLETED PHASE2

The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

NCT05133297

Rheumatoid Arthritis

COMPLETED PHASE2

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055

Rhematoid Arthritis

COMPLETED PHASE4

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364

Arthritis, Psoriatic

COMPLETED PHASE3

A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis

NCT02281552

Rheumatoid Arthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-06650833 + tofacitinib

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

400 mg

Tofacitinib

Intervention Type DRUG

11 mg

PF-06650833 + PF-06651600

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

400 mg

PF-06651600

Intervention Type DRUG

100 mg

PF-06650833

Group Type EXPERIMENTAL

PF-06650833

Intervention Type DRUG

400 mg

PF-06651600

Group Type EXPERIMENTAL

PF-06651600

Intervention Type DRUG

100 mg

Tofacitinib

Group Type EXPERIMENTAL

Tofacitinib

Intervention Type DRUG

11 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-06650833

400 mg

Intervention Type DRUG

PF-06651600

100 mg

Intervention Type DRUG

Tofacitinib

11 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female participants between the ages of 18 and 70 years.
* Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
* Diagnosis of RA and meeting the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA with a Total Score ≥6/10.
* The participant has active disease at both Screening and Randomization, as defined by both: ≥6 joints tender or painful on motion, AND ≥6 joints swollen; and fulfills 1 of the following 2 criteria: High sensitivity C reactive protein (hsCRP) \>7 mg/L at Screening (Visit 1) as performed by the central laboratory OR Erythrocyte sedimentation rate (ESR) (Westergren method) \>28 mm h.

Exclusion Criteria

* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
* Participants with a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency.
* Participants with any active or latent infections.
* Participants with positive hepatitis B surface antigen (HBsAg).
* Participants with positive HCV Ab tests will be reflex tested for HCV ribonucleic acid (HCV RNA).
* Any history of either untreated or inadequately treated latent or active tuberculosis (TB) infection, current treatment for active or latent TB infection or evidence of currently active TB,
* History of a major organ transplant (eg, heart, lung, kidney and liver) or hematopoietic stem cell/marrow transplant.
* History of severe allergic or anaphylactoid reaction to kinase inhibitors, or corticosteroid preparations.
* Known history of diverticulitis or symptomatic diverticulosis, perineal abscess or fistulae.
* Participants with malignancy or history of malignancy (including lymphoma, leukemia, or lymphoproliferative disease).
* Pre-existing chronic autoimmune disease (eg, inflammatory bowel disease, systemic lupus erythematosus, moderate-severe atopic dermatitis, dermatomyositis) other than RA. Secondary Sjogren's Syndrome (due to RA) may be included.
* Participants with fibromyalgia will be excluded.
* Previous treatment with total lymphoid irradiation.
* Participants with an oral, tympanic, or temporal temperature of 38°C (100.4°F) or higher at baseline.
* Participants may not receive any live/attenuated vaccine from 30 days prior to randomization during the course of the study, or for 30 days after the last dose of study medication. Participants who have current routine household contact with children who have received varicella or oral polio vaccine within 2 months of first study dose are also excluded.
* History of any lymphoproliferative disorder.
* Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease.
* History of any prior deep vein thrombosis (DVT) or pulmonary embolism \[PE\].
* Recent (within 6 months of screening) myocardial infarction, coronary revascularization, or percutaneous angioplasty with or without placement of a coronary artery stent; acute coronary syndrome; chronic uncompensated heart failure or New York Heart Association Functional Class III or IV; left ventricular assist devices; implanted defibrillators.
* Current severe chronic renal insufficiency or renal failure as defined by persistent (on repeated measurements) eGFR \<60 mL/min per 1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation.
* Any known coagulopathy or hypercoagulant syndrome.
* Presence of any of the following laboratory abnormalities at screening or within the 3 months prior to first study dose:

Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥1.5 x the upper limit of normal (ULN); Participants with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ≤ ULN and other liver function assessments are normal; Absolute neutrophil count of \<1.5 x 109/L (\<1500/mm3). Participants with cyclic (benign ethnic) neutropenia will be excluded; Absolute lymphocyte count of \<0.5 x 109/L (\<500/mm3); Absolute white blood cell (WBC) count of \<3.0 x 109/L (\<3000/mm3); Hemoglobin \<9.0 g/dL (90 g/L); Platelet count ≤100 x 109/L (100,000 cells/mm3) or ≥1000 x 109/L (1,000,000 cells/mm3); Thrombocytopenia, as defined by a platelet count \<100 x 109/L (\<100,000/mm3) at screening visit or within the 3 months prior to first study dose. \[Screening laboratory tests with abnormal results may be repeated once to confirm abnormal results. If results return to normal protocol acceptable limits within the 4-week screening period, the participant may enter the study\].

\- Grade 3 or greater laboratory abnormality based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 toxicity scale, except for the following that are allowed: Grade 3 prothrombin time (PT) secondary to warfarin treatment; Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.

* Participants previously treated with a biologic DMARD (except for up to 25% of participants who may have been treated with 1, and only 1 prior TNF inhibitor) or any other recent DMARD treatment (eg, a JAK inhibitor), or participants currently treated with any other prohibited medications will be excluded.
* Prior use of tofacitinib or other JAK inhibitor in the context of a clinical trial is excluded. Concomitant use of tofacitinib (other than as prescribed by the randomization scheme) or other JAK inhibitor is prohibited.
* Participants who have previously been treated with other, non-TNFa inhibiting biologic DMARDs \[including, abatacept (Orencia®), tocilizumab (Actemra®), Sarilumab (Kevzara®), anakinra (Kineret®), rituximab (Rituxan®) or other selective B lymphocyte depleting agents, or other lymphocyte depleting agents/therapies (such as alemtuzab \[CamPath®\], natalizumab (Tysabri®), alkylating agents \[eg, cyclophosphamide or chlorambucil\], total lymphoid irradiation) are excluded from participation in the study.
* Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of IP used in this study (whichever is longer).
* Any 12-lead electrocardiogram (ECG) performed prior to randomization that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

,,UMHAT - Georgi Stranski" EAD

Pleven, , Bulgaria

Site Status

Medical Diagnostic Laboratory Rusev EOOD

Plovdiv, , Bulgaria

Site Status

MHAT Plovdiv AD

Plovdiv, , Bulgaria

Site Status

DCC Sveti Georgi EOOD

Plovdiv, , Bulgaria

Site Status

Independent Medical Diagnostic Laboratory Mediscan EOOD

Plovdiv, , Bulgaria

Site Status

"Medical Center-Teodora" EOOD

Rousse, , Bulgaria

Site Status

UMHAT "Kanev" AD

Rousse, , Bulgaria

Site Status

Medical Center "Spectar" OOD

Sofia, , Bulgaria

Site Status

MHAT "Lyulin" EAD

Sofia, , Bulgaria

Site Status

"DCC 17 - Sofia" EOOD

Sofia, , Bulgaria

Site Status

Medical Center "N.I. Pirogov" EOOD

Sofia, , Bulgaria

Site Status

UMHAT "Sveti Ivan Rilski" EAD

Sofia, , Bulgaria

Site Status

Manitoba Clinic

Winnipeg, Manitoba, Canada

Site Status